The latest announcement is out from Revive Therapeutics ( (TSE:RVV) ).
Revive Therapeutics announced the results of its annual shareholder meeting, where key decisions included the election of board members and the appointment of Horizon Assurance LLP as the company’s auditor. The board also decided against amending the company’s articles to consolidate common shares, reflecting shareholder feedback. This meeting underscores Revive’s commitment to aligning with shareholder interests and maintaining strategic focus on its therapeutic development programs.
More about Revive Therapeutics
Revive Therapeutics is a life sciences company that specializes in the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures. The company leverages regulatory incentives from the FDA, such as Emergency Use Authorization and Orphan Drug designations, and is currently exploring treatments for nerve agent exposure and long COVID, as well as developing Psilocybin-based therapeutics.
Average Trading Volume: 304,293
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$2.09M
For a thorough assessment of RVV stock, go to TipRanks’ Stock Analysis page.